Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAN, Africa, arm, authentication, batch, biostatistical, Brazil, Chevron, CI, Claudication, coating, Colon, concomitant, CRO, dedicated, depicted, dialogue, Directionally, Donanemab, Evotec, extranuclear, fatal, Florida, foot, Fortune, inflationary, intercompany, Interval, intraperitoneal, irregular, ISO, ITGC, Korea, leader, leftmost, MD, mice, minute, mITT, muscular, neurondegeneration, NIST, Northeast, opportunistic, outperformed, overview, PhD, prejudice, preliminarily, purple, realign, registry, reposition, rightmost, riluzole, SE, Singapore, SOC, South, Summit, TM, toluidine, traceability, transgenic, unavailability, undermine, underpowered, Zealand
Removed:
arranged, attribution, broader, close, compelling, core, counseling, deducting, diverse, expansion, furlough, globally, hippocampal, house, iii, implied, investee, jeopardizing, largely, linking, Northwest, Pacific, parallel, path, pharmacodynamic, pharmatrophix, point, psychological, PTY, qualitative, reclassified, repaid, reviewed, shut, shutdown, SOX, spread, subsection, suggest, tau, training, underwriting, vest, Virginia, wholesaler
Filing tables
Filing exhibits
Related press release
ATHA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Form S-3 No. 333-261073 of Athira Pharma, Inc.; and
(2)
Form S-8 Nos. 333-263907, 333-254735 and 333-270792 pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan; and 333-248910 pertaining to the 2020 Equity Incentive Plan, the 2020 Employee Stock Purchase Plan, and the 2014 Equity Incentive Plan, as amended, of Athira Pharma, Inc.
of our report dated February 22, 2024, with respect to the consolidated financial statements of Athira Pharma, Inc., included in this Annual Report (Form 10-K) of Athira Pharma, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
Seattle, Washington
February 22, 2024